NFE2L2 and mantle cell lymphoma: Our results offered new insights into the mechanisms of MCL in the treatment of AS and provided a therapeutic approach that limit plaque progression by suppressing macrophage ferroptosis via binding to the Arg483 site of KEAP1 with NRF2 competitively.